Please upgrade your browser.
Rutgers Cancer Institute of New Jersey Collaborates with Big Ten Cancer Research Consortium on Clinical Trial for Metastatic Kidney Cancer
n conjunction with the Big Ten Cancer Research Consortium (BTCRC), Rutgers Cancer Institute of New Jersey has opened a clinical trial for patients with kidney cancer that has spread to other parts of the body (metastatic).
"Renal mass biopsy for a small renal mass can be performed accurately," the authors write. "A second biopsy should be considered in nondiagnostic biopsy cases."
The tumor vaccine MGN1601 was designed and developed for treatment of metastatic renal cell carcinoma (mRCC). MGN1601 consists of a combination of fourfold gene-modified cells with the toll-like receptor 9 agonist dSLIM, a powerful connector of innate and adaptive immunity.
Developments in the field of immuno-oncology (I-O) have ushered in a new era of hope in cancer care. This new concept has forced scientists and clinicians to think beyond the organ of origin of the tumor and wonder about the dynamic interaction between the tumor and its environment.
Duke University researchers have discovered a promising target for renal cell carcinomas
"Varlilumab is an attractive candidate for combination immunotherapy across a variety of cancers due to its target's restricted expression and strong activity in a variety of tumor models, as well as positive data and a favorable safety profile from our Phase 1 study."
This online group provides a safe, confidential space where participants can discuss the unique challenges of living with this illness while receiving support, information and guidance.
Mundipharma EDO GmbH have entered into an agreement for the development and testing of a DRP™ biomarker for Mundipharma EDO’s lead compound EDO-S101
"We are excited at the prospect of our partner Mundipharma EDO moving into Phase I with a DRP™ biomarker developed by MPI A/S,"
Cancer / Oncology Neurology / Neuroscience Melanoma / Skin Cancer Radiology / Nuclear Medicine Nivolumab combined with radiation therapy may be new treatment option
Nivolumab has been approved by the Food and Drug Administration to treat advanced non-small cell lung cancer, renal cell carcinoma, and melanoma; however, the impact of nivolumab on brain metastases is unclear.
The highest response rates were observed in patients with a high Fuhrman grade or sarcomatoid features (22%), grade 4 tumors (25%), or sarcomatoid histology (33%). Overall, 46% of patients had some degree of tumor shrinkage, the authors reported.
|Powered by NeonCRM|